-
-
Finance -
Finance -
Finance -
Pharma & Human Health
Editor’s Choice
Editor's Choice
EMIH and MTIG join forces with Microbiome Times on important deal-making event, taking place Brussels 2025
Microbiome Times Magazine, the microbiome industry’s leading B2B publication, is pleased to announce its collaboration with the coalition groups European Microbiome Innovation for Health (EMIH) and Microbiome Therapeutics Innovation Group (MTIG) for its upcoming Microbiome […]
Editor's Choice
AnonyMine: a platform enabling anonymisation and simulation of microbiome and clinical data
Reusing data collected in clinical studies is of strong scientific and economic interest. Anonymisation has emerged as a solution to extend data life, while providing regulatory compliance and privacy protection. Nevertheless, true anonymisation of complex […]
Editor's Choice
Ferring v Finch: Ripples from the Decision
Three patent claims, one present in each of three US patents held by the Finch Therapeutics Group Inc. (Finch), have been found to have been infringed by Ferring Pharmaceuticals Inc.’s (Ferring) activities in the US […]
In Case you Missed it:
Editor's Choice
EMIH and MTIG join forces with Microbiome Times on important deal-making event, taking place Brussels 2025
Microbiome Times Magazine, the microbiome industry’s leading B2B publication, is pleased to announce its collaboration with the coalition groups European Microbiome Innovation for Health (EMIH) and Microbiome Therapeutics Innovation Group (MTIG) for its upcoming Microbiome […]
Pharma & Human Health
Next-Generation Sequencing for Microbial Community Profiling
On-Demand Webinar Learn about utilizing next-generation sequencing (NGS) to analyze the genetic diversity and function of complex microbial communities. Compared to culture-based methods, powerful techniques like metagenomics and metatranscriptomics can provide a more comprehensive and […]
Webinar
Microbial Community Profiling Webinar
To learn more about how microbial profiling is being used to study human disease, visit the Illumina Metagenomics page.
Pharma & Human Health
Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the FDA for treatment of Duchenne Muscular Dystrophy
GN Corporation’s Neu REFIX Beta glucan, made in Japan has received both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (US FDA) for treatment of Duchenne […]
Animal Health
From the Very Small to the Big Picture: A New Era in Microbiology
Microbes were the only life form on Earth for most of the history of our planet. Even today, they still make up the majority of species that are vital to the health of our planet. […]
Finance
Abolis Biotechnologies Secures €35M to Accelerate R&D in Innovative Biomanufacturing & Microbiome Solutions
Abolis Biotechnologies, a company specializing in industrial solutions using microorganisms, announced the closing of a €35 million financing round led by an international consortium of investors. This funding will fuel the company’s expansion into global […]
Editor's Choice
AnonyMine: a platform enabling anonymisation and simulation of microbiome and clinical data
Reusing data collected in clinical studies is of strong scientific and economic interest. Anonymisation has emerged as a solution to extend data life, while providing regulatory compliance and privacy protection. Nevertheless, true anonymisation of complex […]
Pharma & Human Health
ProDigest Awarded FDA Contract to Provide a Preclinical Gastrointestinal Model: SHIME®
ProDigest has been awarded a contract to provide a SHIME® (Simulator of Human Intestinal Microbial Ecosystem) technology platform for full gut simulation to the US Food and Drug Administration (FDA), National Center for Toxicological Research. […]
